Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)

Jens Faber21 enrolled

Overview

Purpose: The purpose of the study is to examine if treatment with liothyronine increases left ventricular ejection fraction (LVEF) in patients with stable, chronic heart failure.

The patients are examined 3 times. At baseline, after 3 months and after 6 months.After the examination is performed, they begin the study medication while admitted at Dept. of Cardiology, Herlev Hospital, for cardiac monitoring.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Heart Failure Low T3 Syndrome

Interventions

LiothyronineDRUG

Liothyronine 40 microgram per day

LiothyronineDRUG

3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with stable, chronic systolic heart failure * T3 ≤1.4 nmol/l in two blood samples, TSH is to be normal * LVEF ≤ 45 % on prior echocardiography Exclusion Criteria: * Established thyroid illness * Atrial fibrillation/flutter * More than 20% ventricular extrasystoles * Severe chronic obstructive lung disorder * Pregnancy. Pregnancy testing will be done for fertile women * Age \< 18 years

Locations (1)

Herlev Hospital, Dept. of Endocrinology

Herlev, Denmark

Outcomes

Primary Outcomes

left ventricle ejection fraction

The effect of liothyronine treatment in low dose in 3 months on LVEF.

Time frame: 3 months

Secondary Outcomes

Body composition

The effect of 3 months low dose liothyronine treatment on body composition in patients with heart failure.

Time frame: 3 months

Quality of Life, questionaire

The effect of 3 months low dose liothyronine treatment on quality of life, assessed by SF-36 and Minnesota Living with Heart Failure questionnaires in patients with heart failure.

Time frame: 3 months

YKL-40, YNF-alpha, hsCRP and IL-6

The effect of 3 months low dose liothyronine treatment on low grade inflammation assessed by measurement of pro-inflammatory markers in patients with heart failure.

Time frame: 3 months

RBP 4, HBA1C, adiponectin (high and low weight), glucose and HOMA-1

The effect of 3 months low dose liothyronine treatment on metabolic status in patients with heart failure.

Time frame: 3 months

GDF 8, SHBG, CK and PINP

The effect of 3 months low dose liothyronine treatment on the extrathyroidal thyroid effect in patients with heart failure.

Time frame: 3 months

NT-proBNP, EDV and ESV

The effect of 3 months low dose liothyronine treatment on heart function in patients with heart failure.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.